IMMUNOMODULATORY THERAPIES FOR PREVENTING THROMBOSIS IN IMMUNE-MEDIATED MICROVASCULAR THROMBOTIC DISEASES

Z.Ch Kurbanova; S.A Babadjanov; U.A Begmatova

Authors

Z.Ch. Kurbanova Scientific Supervisor: Doctor of Science, Associate Professor Tashkent State Medical University, Tashkent, Uzbekistan
S.A. Babadjanov Scientific Consultant: Doctor of Medical Sciences Tashkent State Medical University, Tashkent, Uzbekistan
U.A. Begmatova Laboratory Work of a Master's Student Tashkent State Medical University, Tashkent, Uzbekistan

Keywords:

Immunomodulatory therapy, microvascular thrombosis, autoimmune diseases, IL-6 antagonists, TNF inhibitors, rituximab, anticoagulants

Abstract

Immune-mediated microvascular thrombotic diseases (IMTD), such as systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), increase the risk of microvascular thrombosis due to chronic inflammation and autoimmune activity. While anticoagulant therapy is crucial for managing thrombotic events, immunomodulatory therapies may provide additional benefits by targeting underlying immune dysfunction. This study evaluated the efficacy of biologic agents (IL-6 antagonists, TNF inhibitors, rituximab) and complement inhibitors in reducing thrombotic risk over 12 months in 50 patients with IMTD (aged 18–65). Inflammatory markers (CRP, IL-6) and thrombotic indicators (D-dimer, fibrinogen) were elevated at baseline and significantly decreased post-therapy (p<0.01). Rituximab reduced antibody levels by 30% in SLE patients (p<0.05), with a 15% reduction in thrombotic events. IL-6 antagonists decreased inflammation and thrombotic risk by 20% (p=0.03). However, bleeding risk was observed in 8% of patients. These findings highlight the potential of immunomodulatory therapies as adjuncts to anticoagulants, though larger trials are needed.

Downloads

Download data is not yet available.

References

1. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-27. doi: 10.1002/art.10187

2. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi: 10.1111/j.1538-7836.2006.01753.x

3. Weitz JI, Jaffer IH, Fredenburgh JC. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2017;37(3):404-12. doi: 10.1161/ATVBAHA.116.308392

4. Bottazzi B, Doni A, Garlanda C, Mantovani A. The long pentraxin PTX3 as a protagonist of inflammation. Immunol Rev. 2010;233(1):9-25. doi: 10.1111/j.0105-2896.2009.00858.x

5. Zandman-Goddard G, Orbach H, Agmon-Levin N, Amital H, Szekanecz Z, Szegedi G, et al. Thrombosis in autoimmune diseases: a role for immunosuppressive treatments? Semin Arthritis Rheum. 2016;46(2):244-50. doi: 10.1016/j.semarthrit.2016.05.002

6. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi: 10.1002/art.37715

7. Favaloro EJ, Lippi G. Laboratory testing in the era of direct oral anticoagulants: a practical approach. Semin Thromb Hemost. 2015;41(3):277-91. doi: 10.1055/s-0035-1546827

8. Weitz JI, Fredenburgh JC, Eikelboom JW. A test in context: D-dimer. J Am Coll Cardiol. 2017;70(19):2411-20. doi: 10.1016/j.jacc.2017.09.024

9. Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med. 2010;38(2 Suppl):S26-34. doi: 10.1097/CCM.0b013e3181c98d21

10. Noris M, Remuzzi G. Pentraxin 3 and the vasculature: a focus on cardiovascular disease. Nat Rev Cardiol. 2016;13(11):695-704. doi: 10.1038/nrcardio.2016.128